Table 2.
Culture isolates in patients managed with and without ALT.
| Culture Isolates | Frequency (% of the Total) |
ALT in Therapeutic Management (Salvage Achieved) | No ALT in Therapeutic Management (Salvage Achieved) |
|---|---|---|---|
| Gram-positive cocci | 34 (58.6) | ||
| CoNS | 24 | 21 (16) | 3 (2) |
| S. aureus | 5 | 2 (1) | 3 (0) |
| Enterococci | 1 | - | 1 (1) |
| Streptococci | 4 | 2 (2) | 2 (2) |
| Gram-positive bacilli | 1 (1.7) | ||
| Corynebacterium spp. | 1 | 1 (1) | - |
| Gram-negative bacilli | 18 (31.1) | 13 (6) | 5 (0) |
| E. coli | 4 | 4 (3) | - |
| ESBL-producing E. coli | 1 | 1 (0) | - |
| Klebsiella spp. | 2 | 1 (0) | 1 (0) |
| Enterobacter cloacae | 4 | 4 (1) | - |
| Enterobacter asburiae | 1 | 1 (0) | - |
| Pseudomonas spp. | 1 | - | 1 (0) |
| Serratia marcescens | 1 | - | 1 (0) |
| Burkholderia spp. | 3 | 1 (1) | 2 (0) |
| Acinetobacter spp. | 1 | 1 (1) | - |
| Candida spp. | 2 (3.4) | - | 2 (0) |
| Polymicrobial | 3 (5.2) | 2 (2) | 1 (0) |
| Total | 58 (100) | 41 (28) | 17 (5) |
ALT: Antibiotic lock therapy. CoNS: Coagulase-negative staphylococci. ESBL: Extended spectrum beta-lactamase.